Economic impact of potential drug–drug interactions in opioid analgesics

References

• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• Altman R. Practical considerations for the pharmacologic management of osteoarthris. Am J Manag Care 2009;15:S236-S243
   PubMedGoogle Scholar
• Nicholas MK, Molloy AR, Brooker C. Using opioids with persisting noncancer pain: a biopsychosocial perspective. Clin J Pain 2006;22:137-46
   PubMedGoogle Scholar
• Hartshorn EA, Tatro DS. Principles of drug interactions. In: Tatro DS, ed. Drug Interaction Facts, 5th edn. St. Louis: Facts and Comparisons, 1996
   Google Scholar
• Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med 2009;10:S20-9
   Web of Science ®Google Scholar
• Prescribing Information, OxyContin® (oxycodone hydrochloride controlled-release) Tablets Purdue Pharma L.P. Stamford, CT 301734-0C May 10, 2010
   Google Scholar
• Kummer O, Hammann R, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2010. [Epub ahead of print]
   Google Scholar
• Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010;66:977-85
   Google Scholar
• Chien JY, Mohutsky MA, Wrighton SA. Physiological approaches to the prediction of drug-drug interactions in study populations. Curr Drug Metab 2003;4:347-56
   PubMed Web of Science ®Google Scholar
• Shou M LY, Lu P, Tang C, et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2000;2:17-36
   Google Scholar
• Reducing and preventing adverse drug events to decrease hospital costs. Research in Action, Issue 1. AHRQ, Agency for Healthcare Research and Quality http://www.ahrq.gov/qual/aderia/aderia.htm. 2001. Accessed July 26, 2010
   Google Scholar
• Bates D, Spell N, Cullen D, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11
   PubMed Web of Science ®Google Scholar
• Classen D, Pestotnik S, Eans R, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;227:301-6
   Google Scholar
• Saurat J-H, Guerin A, Yu A, et al. High prevalence of potential drug–drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010;220:128-37
   PubMed Web of Science ®Google Scholar
• Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics (Sao Paulo) 2006;61:515-20
   PubMedGoogle Scholar
• Becker ML, Hofman A, Stricker BHC. Increasing exposure to drug–drug interactions between 1992 and 2005 in people aged =>55 years. Drugs Aging 2008;25:145-52
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Labhsetwar S, Puenpatom R, et al. Exposure to potential CYP450 prevalence of exposure to potential CYP450 pharmacokinetic drug–drug interactions among patients with chronic low back pain taking opioids. Pain Pract 2010. [Epub ahead of print]
   Google Scholar
• Pergolizzi J, Labhsetwar S, Puenpatom R, et al. Exposure to potential CYP450 pharmacokinetic drug–drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract 2010 doi: 10.1111/j, 1533-2500
   Google Scholar
• Haijar E, Hanlon J, Artz M, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother 2003;1:82-9
   PubMedGoogle Scholar
• McCaffery M, Pasero M. Pain: Clinical Manual. Philadelphia: Mosby, 1999
   Google Scholar
• Slone Epidemiology Center. Patterns of Medication Use in the United States 2006. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf. Accessed October 5, 2010
   Google Scholar
• Nguyen J, Fouts M, Kotabe S, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006;4:36-41
   PubMedGoogle Scholar
• Gurwitz J, Field T, Harrold L, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16
   PubMed Web of Science ®Google Scholar
• Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005;29(5 Suppl):S90-103
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler D. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs Aging 2003;63:649-71
   Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11-18S
   PubMed Web of Science ®Google Scholar
• Cadet P. Mu opiate receptor subtypes. Med Sci Monit 2004;10:MS28-32
   PubMedGoogle Scholar
• Hale M, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2007;8:175-84
   Google Scholar
• Robins J, Mark S, Newey W. Estimating exposure effects by modeling the expectation of exposure conditional on confounders. Biometrics 1992;48:479-95
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24
   Web of Science ®Google Scholar
• Barnett V, Lewis T. Outliers in Statistical Data, 3rd edn. Chichester, UK: Wiley, 1994
   Google Scholar
• SAS 9 on Microsoft Windows, 2008, SAS Institute Inc., Cary, NC, USA
   Google Scholar
• Armstrong S, Cozza K. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003;44:167-71
   PubMed Web of Science ®Google Scholar
• Solberg L, Hurley J, Roberts M, et al. Measuring patient safety in ambulatory care: potential for identifying group drug–drug interaction rates using claims data. Am J Manag Care 2005;10:753-9
   Google Scholar
• Dickson M, Bramley T, Kozma C, et al. Potential drug–drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health-System Pharm 2008;65:1983-91
   Google Scholar
• Qato D, Alexander G, Conti R, et al. Use of prescription and over-the-counter medications and dietatry supplements among older adults in the United States. JAMA 2008;300:2867-78
   PubMed Web of Science ®Google Scholar